Literature DB >> 2933950

Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition.

J H Bauer, S Sunderrajan, G Reams.   

Abstract

The renal effects of the calcium entry-blocking drugs diltiazem, nifedipine, verapamil and nitrendipine are reviewed. Although nifedipine stimulates plasma renin activity on a short-term basis, none of the calcium entry blockers produces a clinically significant sustained effect on any of the components of the renin-angiotensin-aldosterone system. Although all of the calcium entry blockers effectively lower blood pressure, none adversely affects renal function; glomerular filtration rate and effective renal plasma flow are maintained. Diltiazem may increase glomerular filtration rate via attenuation of the intrarenal effects of angiotensin II or norepinephrine. Although diltiazem and nifedipine increase salt and water excretion on a short-term basis, none of the calcium entry blockers produces a clinically significant sustained effect on salt and water excretion; serum electrolytes, urinary sodium and potassium excretion, body fluid composition and body weight are unchanged. Thus, calcium entry blockers can be expected to assume a prominent role in the treatment of hypertension because of their ability to lower blood pressure while preserving renal perfusion and function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933950     DOI: 10.1016/0002-9149(85)90546-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Calcium entry blocker nicardipine inhibits sodium and inorganic phosphate reabsorption independent of renal circulation in dogs.

Authors:  F Goto; I Watanabe
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

Review 2.  Renal effects of calcium entry blockers.

Authors:  L M Ruilope; J M Alcazar
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Influence of antihypertensive therapy on renal function.

Authors:  U Frei; R Schindler; K M Koch
Journal:  Clin Investig       Date:  1992

Review 4.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

5.  The haemodynamic effects of long term felodipine therapy in previously untreated essential hypertension.

Authors:  S Capewell; C G Wathen; W J Hannan; A L Muir
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Renal effects of manidipine hydrochloride. A new calcium antagonist in hypertensive patients.

Authors:  T Takabatake; H Ohta; T Sasaki; S Satoh; K Ohta; T Ise; K Kobayashi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 7.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

8.  Diltiazem maintains renal vasodilation without hyperfiltration in hypertension: studies in essential hypertension man and the spontaneously hypertensive rat.

Authors:  T Isshiki; C Amodeo; F H Messerli; B L Pegram; E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

9.  Clinical evaluation of felodipine in patients with refractory hypertension.

Authors:  H Herlitz; S Björck; G Nyberg; G Granérus; M Aurell
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  Safety of telmisartan in patients with arterial hypertension : an open-label observational study.

Authors:  Martin C Michel; Herbert Bohner; Jürgen Köster; Rafael Schäfers; Uwe Heemann
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.